SynthesisFrontiers in oncology2026
Feasibility of neoadjuvant immunochemotherapy in potentially resectable non-small cell lung cancer: a single-arm meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Potentially resectable, stage IIB-IIIB non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge. Factors such as tumor size, location, or nodal status often preclude initial complete resection, necessitating novel strategies to improve prognosis. While neoadjuvant immunochemotherapy has demonstrated promise in metastatic/advanced NSCLC, evidence for its application in the potentially resectable setting remains limited. This study synthesizes the existing evidence and evaluates the efficacy, pathological response rates, and frequency of treatment-related events associated with neoadjuvant immunochemotherapy in this specific patient population. Methods: A single-arm meta-analysis was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)-NMA guidelines. A systematic search of databases (PubMed, Embase, and Cochrane) was performed up to 9 December 2025, for studies investigating neoadjuvant anti-PD-1/PD-L1 therapy combined with chemotherapy in potentially resectable NSCLC. Data were analyzed using STATA 14. A random-effects model was employed for significant heterogeneity ( Results: A total of 34 studies involving 1,885 patients were included. The pooled surgical resection rate was 76.0% (95% CI: 70.0%-82.0%; Conclusion: This single-arm meta-analysis suggests that for patients with potentially resectable NSCLC, neoadjuvant immunochemotherapy followed by surgery shows promising short-term pathological response rates and acceptable rates of treatment-related events, indicating potential feasibility. However, because of the lack of comparator data and mature long-term survival outcomes, its definitive clinical benefit remains uncertain. Our results provide preliminary evidence and rationale for initiating randomized controlled clinical trials in this population to compare the efficacy and safety of surgery after neoadjuvant immunochemotherapy versus current standard therapy. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024579329.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.